GoodRx, Boehringer Ingelheim Launch Initiative for Humira Biosimilar
Boehringer’s adalimumab-adbm is being offered on GoodRx’s platform for $550 per two-pack, a 92% discount from the Humira list price, according to the companies.
Boehringer Ingelheim Strikes Regenerative Med R&D Deal Spanning MASH & More Liver Diseases
The first FDA-approved MASH drug doesn’t treat patients with liver cirrhosis. A new Boehringer Ingelheim/Ochre Bio collaboration is researching regenerative medicines that could treat patients in this most advanced stage of the fatty liver disease.
presented by
Transforming Patient Care: The Role of AI-Powered Assistants
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Boehringer Ingelheim Places €25M Bet on Sosei’s Novel Approach to Schizophrenia
Sosei Heptares’ schizophrenia drug candidate addresses a novel, difficult-to-drug target for neurological disorders. Boehringer Ingelheim can exercise its option on the small molecule following a Phase 1 test expected to yield data in 2025.
Boehringer Ingelheim’s Liver Drug Data Position It for MASH Clash With Eli Lilly
Preliminary Phase 2 results show 83% of those treated with Boehringer Ingelheim and Zealand Pharma drug survodutide met the main goal of improvement in the fatty liver disease MASH. Boehringer contends this drug has best-in-class potential in a competitive field that includes an Eli Lilly drug that recently posted positive Phase 2 results.
FDA approves Humira biosimilar as first-ever interchangeable monoclonal antibody
Boehringer Ingelheim has shown biosimilar manufacturers the way to win interchangeability with the world’s highest-grossing drug — but the company’s Cyltezo won't come out until July 2023. Will future Humira competitors have better luck winning an earlier launch date?
These drug patents are expected to expire in 2020
According to a report, drugmakers are expected to lose $17 billion in worldwide sales due to patent expirations this year. Two reports list 18 drugs as losing patent protection or exclusivity, though not all drugs listed here will necessarily face generic or biosimilar competition in 2020.
The Funding Model for Cancer Innovation is Broken — We Can Fix It
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
Singapore biotech could get more than $1B from Boehringer Ingelheim under partnership
The German drugmaker announced a partnership with Enleofen to develop the company's suite of preclinical antibodies targeting IL-11 in diseases like NASH.
Boehringer Ingelheim dumps NASH drug program amid concerns over drug interactions
BI said it would continue to develop the drug, BI 1467335, in other diseases and remain committed to NASH overall. Shares of the Australian company from which it licensed the drug, Pharmaxis, fell more than 40%.
Boehringer Ingelheim, MD Anderson to develop cancer drugs under research partnership
The two organizations are placing particular emphasis on lung and gastrointestinal cancers, as well as drug targets like KRAS mutations.
Boehringer Ingelheim to acquire Swiss cancer vaccine developer for up to 325M euros
The deal includes an upfront payment and up to 100 million euros in milestones, equaling $364.5 million. Amal's lead candidate is a vaccine for colorectal cancer expected to enter the clinic later this month.
Health Executives on Digital Transformation in Healthcare
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
It’s not about what blockchain can do in healthcare, but what it’s already doing
A panel discussion at the upcoming MedCity INVEST meeting in Chicago will look at real-world applications of blockchain technology in healthcare and biopharma.
Boehringer Ingelheim, IBM to study blockchain in clinical trials
At the ongoing HIMSS conference in Orlando, Florida, the companies' Canadian divisions said their partnership would mark the technology's first use in clinical trials in Canada.
Biosimilars market set to nearly quadruple in next five years, report finds
Market forecast rosy, though market in United States remains young.
Qualcomm Life, Philips team up on connected health
Qualcomm Life also announced Tuesday that it would work with Boehringer Ingelheim Pharmaceuticals to develop a disposable, wireless connectivity module for the drug company's Respimat inhaler.
Centrexion nabs three non-opioid pain drugs from Boehringer Ingelheim
Boehringer Ingelheim offloaded the drugs, it said in a statement. because it's shifting away from pain medications to focus on CNS diseases like Alzheimer's, schizophrenia and depression.